Olmesartan /Amlodipine Mylan (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartan /Amlodipine Mylan, is a angiotensin II receptor blocker presented as a fixed‑dose combination for oral use. It treats hypertension, often in patients who require additional blood pressure control beyond what a single agent can provide.

GNH USA supplies Olmesartan /Amlodipine Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan /Amlodipine Mylan is used in cardiovascular therapy to manage high blood pressure through combined angiotensin receptor blockade and calcium‑channel antagonism. - Hypertension: Improves blood pressure control when monotherapy is insufficient. - Hypertensive patients with concomitant edema: Reduces peripheral edema associated with calcium‑channel blocker therapy. - High‑risk cardiovascular patients: Lowers the risk of stroke and myocardial infarction by achieving target blood pressure levels.

Adverse reactions may occur with any antihypertensive regimen and should be monitored during therapy.

Common Side Effects: - Dizziness or light‑headedness - Peripheral edema - Headache - Flushing - Fatigue - Palpitations

Serious or Rare Side Effects: - Angio‑edema - Severe hypotension - Hepatic enzyme elevation - Acute kidney injury - Myocardial infarction in patients with severe aortic stenosis - Hyperkalemia

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters. - Renal function: Evaluate baseline creatinine and adjust if impairment is present. - Hepatic function: Use caution in patients with liver disease. - Electrolytes: Monitor potassium levels, especially if combined with potassium‑sparing diuretics. - Pregnancy: Contraindicated in the second and third trimesters; avoid use. - Elderly: Start at lower dose and titrate slowly. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Olmesartan /Amlodipine Mylan may interact with several drug classes; careful review of a patient’s medication list is essential.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, aliskiren) – increased risk of renal dysfunction and hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole) – may raise amlodipine levels.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) – can blunt antihypertensive effect and affect renal function. - Diuretics – may enhance hypotensive response. - Lithium – increased risk of lithium toxicity. - Simvastatin – amlodipine may increase statin concentration, raising myopathy risk.